Andrew Wiese, PhD, MPH
Pharmacoepidemiology, infectious disease, sickle cell disease, maternal and child health, substance use disorder
Andrew Wiese, PhD, is an Assistant Professor in the Division of Pharmacoepidemiology, Department of Health Policy at Vanderbilt University Medical Center (VUMC). His research focus is on leveraging observational studies to provide real-world evidence of the safety and efficacy of commonly used medications and vaccines, especially understudied populations such as individuals with sickle cell disease.
His current work includes using the TN Medicaid Mother-Child Linked Cohort (MCLC) data platform to characterize the safety of medication use during pregnancy and in the postpartum period, as well as leveraging the CDC-funded national Sickle Cell Data Collection (SCDC) program to examine treatment utilization, safety and effectiveness among individuals living with sickle cell disease in the United States.
Dr. Wiese has published widely using administrative data to examine the risks of opioid analgesic use, including the risk of serious infections associated with prescribed opioid use and the risk of serious-opioid related harms among women using prescribed opioids in the postpartum period. He has also published more broadly in the field of pharmacoepidemiology to help inform our understanding of the effectiveness of the U.S. childhood pneumococcal conjugate vaccine program, the effectiveness of current and novel treatments for opioid use disorder, and the safety of post-discharge opioid prescribing among individuals hospitalized with traumatic injury.
Dr. Wiese is the Principal Investigator for a National Institute on Drug Abuse funded-career development award examining the impact of benzodiazepine restriction policies on benzodiazepine-related harms among the Full TN Medicaid Cohort. Dr. Wiese is also a Co-Investigator on a Eunice Kennedy Shriver National Institute of Child Health & Human Development-funded study leveraging the TN MCLC data platform to examine outcomes for mothers and children affected by opioids during pregnancy using linkages to external data sources on childhood outcomes from the TN Department of Child Services and TN Early Intervention System. He is also a co-investigator on two CDC-funded projects, including the Sickle Cell Data Collection (SCDC) program and Emerging Infections Program (EIP). He is also a former appointee in the BIRCWH (Building Interdisciplinary Research Careers in Women’s Health) K12 program at VUMC.
A full CV is available upon request.
Recent & Highlighted Research
Spieker AJ, Adgent MA, Osmundson SS, Phillips SE, Mitchel E Jr, Leech AA, Grijalva CG, Wiese AD. The impact of different strategies for modeling associations between medications at low doses and health outcomes: a simulation study and practical application to postpartum opioid use. Am J Epidemiol. 2024 Jun 21:kwae147. doi: 10.1093/aje/kwae147. Epub ahead of print. PMID: 38907307.
Hart K, Medvecz AJ, Vaidya A, Dusetzina S, Leech AA, Wiese AD. Opioid and non-opioid analgesic regimens after fracture and risk of serious opioid-related events. Trauma Surg Acute Care Open. 2024-07-14; 9(1):e001364. doi:10.1136/tsaco-2024-001364. PubMed PMID: 39021730 Citation in REDCap PMC11253739.
Wiese AD, Phillippi JC, Muhar A, Polic A, Liu G, Loch SF, Ong HH, Su WC, Leech AA, Reese T, Wei WQ, Patrick SW. Performance of Phenotype Algorithms for the Identification of Opioid-Exposed Infants. Hosp Pediatr. 2024-06-01. doi:10.1542/hpeds.2023-007546. PubMed PMID: 38804051 Citation in REDCap PMC11137624.